Multidirectional percutaneous drilling and autologous bone marrow injection for the treatment of femoral diaphyseal nonunions: a prospective interventional study
Received 20 March 2019
Accepted for publication 25 July 2019
Published 19 August 2019 Volume 2019:15 Pages 1003—1011
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Ming Li,1,* Yutong Meng,2,* Yi Li,1 Anhua Long,3 Houchen Lv,1 Pengbin Yin,1 Licheng Zhang,1 Peifu Tang1
1Department of Orthopaedics, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China; 2Department of Orthopedics, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, People’s Republic of China; 3Department of Orthopaedics, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, People’s Republic of China;
Correspondence: Peifu Tang; Licheng Zhang
Department of Orthopedics, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing 100853, People’s Republic of China
Tel +86 10 6821 2342
Email [email protected]
*These authors contributed equally to this work
Background: To examine the outcomes of multidirectional percutaneous drilling and autologous concentrated bone marrow (BM) transplantation for atrophic femoral diaphyseal nonunion characterized by intact hardware and mechanical stability at the nonunion site.
Methods: Fourteen patients (22–63 years of age) were admitted to our hospital with atrophic femoral diaphyseal nonunion. All patients were treated with a combination of multidirectional percutaneous drilling and autologous concentrated BM transplantation. Radiographic evaluation was conducted every month after transplantation until bone healing was achieved.
Results: Bony union was achieved in 13 of the 14 patients (92.9%) after an average of 3.9 months (range: 2.5–6 months). The average radiographic union scale in tibial (RUST) scale score improved significantly from the preoperative period (6.15±1.21) to follow-up (11.23±0.73; P<0.05). The mean follow-up after transplantation was 31.4±9.5 months (range: 18–50 months). At the final follow-up, the quality of function had improved significantly, allowing a return to normal activities.
Conclusion: Combined multidirectional percutaneous drilling and autologous concentrated BM transplantation is an easy, safe, inexpensive, and efficacious method to treat atrophic femoral diaphyseal nonunion characterized by intact hardware and mechanical stability at the nonunion site.
Trial registration number: ISRCTN29808592
Keywords: autologous bone marrow injection, multidirectional percutaneous drilling, femoral diaphyseal fracture, nonunion
Diaphyseal femoral fractures occur in both the young and the elderly. Their causes are diverse, as are the treatment options used to treat both the fractures and the associated injury.1 Current methods include intramedullary nailing, plate fixation, and external fixation. While the results are generally favorable, delayed union or nonunion occurs in some cases. Böstman et al reported a 4% delayed or nonunion rate in fractures treated with locking plate fixation.2 Reamed interlocking intramedullary nailing was shown to yield better clinical results than plate fixation, with a nonunion rate of 0.9–1.1%.3,4 However, despite these improved outcomes, patients with nonunion of the diaphyseal femur will inevitably suffer serious complications, including limb deformity or shortening, degeneration of neighboring joints, and local pain.
The treatment of nonunion is a challenge to orthopedic surgeons. In patients with nonunion of diaphyseal femoral fractures, various treatment strategies based on the above-described methods have been proposed. A prerequisite is careful classification of the nonunion, as this will guide the treatment choice. For patients with atrophic femoral diaphyseal nonunion, autologous cancellous bone is a fairly common practice, with the most common autologous graft donor site being the iliac crest.5 Autologous bone grafts, analogous bone grafts, and bone substitutes are additional therapeutic options.6 The complications that follow treatment include donor site pain, blood loss, increased operative time, and a risk of infection.7,8 The incidence of morbidities related to bone grafts is as high as 22%, with 12-month donor site pain occurring in up to 45% of patients.9,10
To minimize the drawbacks associated with traditional bone grafting, percutaneous approaches have been developed for harvesting autologous bone marrow (BM).11–13 These approaches are based on osteo-inducing cells harvested from the iliac crest and injected directly into the fracture site. BM grafted using this method is easy, safe, and relatively non invasive and can be performed under local anesthesia with minimal secondary local damage. However, not all patients who undergo this procedure experience satisfactory healing, and the incidence of nonunion after BM injection continues to be high, at 18–37%.14–16
One difficulty in treating nonunion is that the involved site is stiff and not easily handled. In standard bone-grafting procedures, resection of nonviable bone and the intervening nonunion tissue is necessary.17 However, in previously reported percutaneous BM grafting procedures, no attempts were made to remove the intervening callus or fibrous tissue from the nonunion site.13,16,18–20 This omission would make it difficult to inject the entire volume of BM, and the injected marrow may leak through the gap between bone and soft tissue. We, therefore, hypothesized that multidirectional percutaneous drilling of the nonunion site would produce an ideal incubation bed for fixing the BM graft in position while simultaneously promoting the revascularization of intervening fibrous tissue and inducing osteoinductive factors locally in the bone matrix, thus enhancing bone healing.
Materials and methods
Study population and protocol
This study was a single-center, single-group interventional study conducted at our hospital, a university teaching hospital, from January 2009 to September 2013. Patients aged >18 years with atrophic nonunion, and who underwent percutaneous autologous BM grafting with multidirectional percutaneous pre drilling procedures, were voluntarily enrolled in the study. Patients with local angular deformity, shortening, fixation problems, or mental comorbidities resulting in poor compliance were excluded. Thus, the final study population consisted of 14 patients with atrophic femoral diaphyseal nonunion who agreed to undergo this novel procedure. The characteristics of the patients are listed in Table 1. The nine males and five females had a mean age of 33.8 years (range: 22–63 years). Eight nonunions involved the left femur and six the right femur. All patients had previously undergone plate or intramedullary nail fixation. Atrophic nonunion of a diaphyseal femoral fracture (International Classification of Diseases 10th edition [ICD-10] code M84.151) was diagnosed according to clinical signs and radiographic examinations. In all of the patients, >9 months had passed since the initial fixation. No visible progressive signs of healing at the fracture site had appeared during the 3 previous consecutive months, thus fulfilling the Food and Drug Administration’s definition of nonunion. All data in this study were collected prospectively. Informed consent was obtained from all individual participants included in the study.
Table 1 Patient characteristics
BM aspiration and concentration
BM was harvested according to a previously published method.21 Briefly, after the patients were placed under general anesthesia, a BM aspiration needle was inserted into the posterior iliac crest. The needle was reoriented repeatedly within the iliac crest to optimize the number of BM cells harvested. Samples obtained from each puncture point were pooled into a BM collection bag containing anticoagulant. Erythrocytes were removed by centrifugation for 10 mins at 1200 g. The remaining aggregates were then centrifuged for 10 mins at 3000 g to remove supernatant plasma and anticoagulants. Finally, a concentrate of BM aspirate (30–40 mL) was collected in a syringe for injection.
Multidirectional percutaneous drilling at the nonunion site and BM grafting
Under fluoroscopic guidance, multiple 4.0-mm steinmann pins were drilled into the nonunion site in various directions to push the intervening soft tissue away. After repeated drilling, a concentrated BM syringe needle was placed in the nonunion gap; the BM was slowly injected for 1 min, and the needle was gradually withdrawn. Figure 1 shows the steps of the procedure, and Figure 2 provides intraoperative photographs of a patient with femoral shaft nonunion.
Figure 1 The steps of the procedure. (A) Fracture nonunion; (B) multiple drilling of the nonunion site from different angles; (C) autologous bone marrow grafting.
Radiographic evaluation (plain anteroposterior and lateral radiographs) was conducted every month for 1 year after transplantation until bone healing was achieved. Healing at the four cortices (medial/lateral/anterior/posterior) was evaluated using the Radiographic Union Scale for Tibial fractures (RUST) classification system,22 which employs 4- to 12-point scales and sums the score for each of the four cortices. Three senior orthopedists judged the healing independently, with the final diagnosis based on the majority opinion.
All data were expressed as mean and SD of the mean using SPSS 22.0 software (IBM Corporation, Armonk, NY, USA). The univariate significance of the comparison between the preoperative and postoperative of RUST score was established through a independent-samples t-test.
All patients reported slight discomfort at the donor site for the first 2 days postoperatively, but the pain was managed sufficiently with oral pain killers administered during the first 24 hrs. No major complications were identified. Of the 14 patients, bony union was achieved in 13 (92.9%) after an average of 3.9 months (range: 2.5–6 months) (Figures 3, 4). Radiographic union was diagnosed by a RUST score ≥10, and the results were confirmed by clinical examination. The average RUST score improved significantly, from 6.15±1.21 preoperatively to 11.23±0.73 at follow-up (P=0.000, P<0.05) (Figure 5). The mean final follow-up duration was 31.4±9.5 months after transplantation (range: 18–50 months). By the final follow-up examination, the patients’ quality of life had significantly improved and a return to normal activities was possible. Only one patient failed to achieve bony union without signs of healing 3 months after BM injection. This patient received an additional plate and autogenous bone grafting at 3 months and achieved bony union within 6 months after the latter procedure.
Figure 5 Analysis of the RUST score between preoperative and postoperative follow-up. Each bar represents the mean ± SD. *P=0.000, P<0.05.Abbreviation: RUST, radiographic union scale in tibial.
Femoral diaphyseal nonunion has long been a challenging clinical problem. Effective surgical treatment of these patients requires a detailed understanding of the pathophysiology and classification of nonunion.23 Fracture union mainly depends on adequate mechanical stabilization and the biological environment (pro-osteogenic cells, growth factors, and vascularization) of the fracture site.24,25 Hypertrophic nonunion is considered to arise from insufficient stability; in these cases, treatment primarily involves stabilization of the fracture. However, atrophic nonunion has a primarily biological, rather than mechanical, etiology26 and thus requires a biological approach to treatment. In this study, the mechanical properties of the nonunion were carefully evaluated by radiographic examination. There were no fixation problems, and all cases were identified as atrophic nonunion. The lack of an appropriate biological stimulus was thus hypothesized to be a major factor leading to nonunion in the study patients.
The standard treatment for nonunion is autologous bone grafting, which is performed to accelerate osteogenesis by stimulating the local microenvironment at the nonunion site. However, the autogenous bone originates mainly from the iliac spine and is harvested during a procedure that is relatively invasive and may cause pain, neurovascular injury, infection, or other complications at the donor site.
To minimize the drawbacks associated with traditional bone grafting, autologous BM grafting for nonunion has been employed, with mixed results. The first report of percutaneous BM grafting of delayed union and nonunion was by Healey et al, in 1990. Their patients had undergone lower-extremity resections for sarcomas affecting bone. Bony union was finally achieved in five of the eight patients (63%).14 With gradual improvements to the technique, bony re union rates after autologous BM grafting have reached 76–82% according to recent studies,15,16 but there remains considerable room for improvement.
Prior to this study, we carefully assessed the drawbacks associated with previously reported autologous BM grafting procedures.13,16,18–20,27,28 A major problem was that in none of them, an attempt had been made to remove the intervening calluses or fibrous tissue from the nonunion site. We, therefore, designed a new procedure that combined the advantages of multidirectional percutaneous drilling with minimally invasive percutaneous supplementation of autologous concentrated BM, thus providing an ideal incubation bed and a strong biological stimulus. Patients treated by this technique achieved a bone union rate of 92.9% (13/14).
BM contains osteogenic progenitors, and its implantation can lead to effective bone regeneration. Both preclinical investigations and clinical studies have demonstrated that BM cells can differentiate into osteoblasts.29–33 In clinical practice, autologous BM is harvested from the iliac crest and implanted at the fracture site. Previous studies have shown a link between the number of progenitors in the graft and the volume of the callus around the nonunion site. In failed cases, the number of transplanted BM stem cells was low.34 In our approach, with the aim of grafting as many osteogenic stem cells as possible, we grafted concentrated aspirates. Hernigou et al demonstrated that mononuclear cells could be concentrated by centrifugation of the BM aspirate, resulting in improved osteogenesis.27 They also hypothesized that the concentrated BM includes stem and other mononuclear cells with osteogenic or angiogenic properties that influence the clinical outcome. Although culture-expanded human BM stromal cells have been used successfully for enhanced fracture healing in nonunion,35 they must be expanded in vitro for several weeks to achieve a sufficient number of cells for transplantation. This delays treatment and increases both the culture-related contamination risk and therapy cost. By contrast, BM concentration is a simple, safe, clean, and low-cost procedure that allows the harvest and transplantation of cells shortly after their aspiration. This advantage recommends the use of BM cell concentrates, instead of expanded purified BM stromal cells, for bone cell therapy.
Resection of the scar and fibrous tissue at the nonunion site is considered essential for the treatment of atrophic nonunion.17 However, for percutaneous cellular transplantation, additional surgery to refresh the nonunion site may disrupt already compromised tissues and increase the risk of continued nonunion, or even lead to further complications such as infection. Moreover, a previous study in humans showed that nonunion tissue at the fracture gap contains osteogenic or chondrogenic progenitor cells.17 Three factors are thought to be essential to the healing process: an adequate number of osteoprogenitor cells, an appropriate scaffold (cell incubation bed), and biologically active molecules.28 In nonunion treated with BM, the marrow is injected both into the gap in the nonunion and around the bones. However, it may be difficult to inject the entire graft and the BM may leak through the gap between the bone and soft tissue. Therefore, the existing fibrous tissue in the fracture gap should be removed, by chipping or drilling, to obtain an ideal cell incubation bed for placement of the concentrated BM. In our procedure, multidirectional percutaneous drilling was performed to cause local damage (microfracture), promote the revascularization of fibrous tissue, and accelerate the inflow of BM cells or growth factors from normal peripheral bone. In addition, hematomas caused by local microfracture help restart the healing process, while cells in the concentrated BM secrete angiogenic cytokines, which promote angiogenesis and thus improve osteogenesis.36
The best indication for the combined use of multidirectional percutaneous drilling and autologous concentrated BM is the treatment of nonunion, especially oligotrophic or atrophic nonunion, which are less biologically active. In our study, this approach led to complete healing in 92.9% of the patients, all of whom had been diagnosed with atrophic nonunion. While the infection may be considered the main risks of the procedure, our study showed that it is safe, simple, and less invasive, and that local or systemic complications did not develop in any of the treated patients. Hernigou et al reported the clinical results of >1000 patients who underwent BM aspiration and none developed complications.19 There are also no reports of infection among any of the published studies on autologous BM grafting for nonunion.11–13,16,18–20,27–29,35 Additionally, because the material injected is autologous BM, there is no risk of disease transmission or an immune reaction.
The therapy proposed in this study combined two simple techniques: multidirectional percutaneous drilling and autologous concentrated BM transplantation under fluoroscopy. Together, they constitute a simple, minimally invasive, and inexpensive method to successfully treat femoral diaphyseal nonunion. Because the results were at least as good as those achieved with other methods, our study demonstrates the utility of this combined technique for treating aseptic nonunion characterized by intact hardware and mechanical stability at the nonunion site.
Ethical approval and informed consent
Ethical approval was obtained by the ethics committee of the Ethics Review Board of Chinese PLA General Hospital. Written informed consent was obtained from all participants.
This work was supported by the Medical Big Data Center of PLA General Hospital (2017MBD-014).
The authors report no conflicts of interest in this work.
1. Neumann MV, Sudkamp NP, Strohm PC. Management of femoral shaft fractures. Acta Chir Orthop Traumatol Cech. 2015;82(1):22–32.
2. Bostman O, Varjonen L, Vainionpaa S, Majola A, Rokkanen P. Incidence of local complications after intramedullary nailing and after plate fixation of femoral shaft fractures. J Trauma. 1989;29(5):639–645. doi:10.1097/00005373-198905000-00019
3. Wolinsky PR, McCarty E, Shyr Y, Johnson K. Reamed intramedullary nailing of the femur: 551 cases. J Trauma. 1999;46(3):392–399. doi:10.1097/00005373-199903000-00007
4. Winquist RA, Hansen ST
5. Niu Y, Bai Y, Xu S, et al. Treatment of lower extremity long bone nonunion with expandable intramedullary nailing and autologous bone grafting. Arch Orthop Trauma Surg. 2011;131(7):885–891. doi:10.1007/s00402-010-1226-9
6. Nauth A, Lane J, Watson JT, Giannoudis P. Bone graft substitution and augmentation. J Orthop Trauma. 2015;29(Suppl 12):S34–S38. doi:10.1097/BOT.0000000000000464
7. Kumar G, Narayan B. Morbidity at bone graft donor sites. In: Banaszkiewicz PA, Kader DF, editors. Classic Papers in Orthopaedics. London: Springer; 2014:503–505.
8. Calori GM, Colombo M, Mazza EL, Mazzola S, Malagoli E, Mineo GV. Incidence of donor site morbidity following harvesting from iliac crest or RIA graft. Injury. 2014;45(Suppl 6):S116–S120. doi:10.1016/j.injury.2014.10.034
9. Robertson PA, Wray AC. Natural history of posterior iliac crest bone graft donation for spinal surgery: a prospective analysis of morbidity. Spine (Phila Pa 1976). 2001;26(13):1473–1476. doi:10.1097/00007632-200107010-00018
10. Goulet JA, Senunas LE, DeSilva GL, Greenfield ML. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res. 1997;339:76–81. doi:10.1097/00003086-199706000-00011
11. Galois L, Bensoussan D, Diligent J, et al. Autologous bone marrow graft and treatment of delayed and non-unions of long bones: technical aspects. Biomed Mater Eng. 2009;19(4–5):277–281. doi:10.3233/BME-2009-0592
12. Goel A, Sangwan SS, Siwach RC, Ali AM. Percutaneous bone marrow grafting for the treatment of tibial non-union. Injury. 2005;36(1):203–206. doi:10.1016/j.injury.2004.01.009
13. Singh AK, Shetty S, Saraswathy JJ, Sinha A. Percutaneous autologous bone marrow injections for delayed or non-union of bones. J Orthop Surg (Hong Kong). 2013;21(1):60–64. doi:10.1177/230949901302100116
14. Healey JH, Zimmerman PA, McDonnell JM, Lane JM. Percutaneous bone marrow grafting of delayed union and nonunion in cancer patients. Clin Orthop Relat Res. 1990;256:280–285.
15. Braly HL, O’Connor DP, Brinker MR. Percutaneous autologous bone marrow injection in the treatment of distal meta-diaphyseal tibial nonunions and delayed unions. J Orthop Trauma. 2013;27(9):527–533. doi:10.1097/BOT.0b013e31828bf077
16. Sugaya H, Mishima H, Aoto K, et al. Percutaneous autologous concentrated bone marrow grafting in the treatment for nonunion. Eur J Orthop Surg Traumatol. 2014;24(5):671–678. doi:10.1007/s00590-013-1369-9
17. Iwakura T, Miwa M, Sakai Y, et al. Human hypertrophic nonunion tissue contains mesenchymal progenitor cells with multilineage capacity in vitro. J Orthop Res. 2009;27(2):208–215. doi:10.1002/jor.20739
18. Guimaraes JA, Duarte ME, Fernandes MB, et al. The effect of autologous concentrated bone-marrow grafting on the healing of femoral shaft non-unions after locked intramedullary nailing. Injury. 2014;45(Suppl 5):S7–S13. doi:10.1016/S0020-1383(14)70013-0
19. Hernigou P, Poignard A, Manicom O, Mathieu G, Rouard H. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br. 2005;87(7):896–902. doi:10.1302/0301-620X.87B7.16289
20. Kassem MS. Percutaneous autogenous bone marrow injection for delayed union or non union of fractures after internal fixation. Acta Orthop Belg. 2013;79(6):711–717.
21. Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am. 2006;88(Suppl 1 Pt 2):322–327. doi:10.2106/JBJS.F.00203
22. Whelan DB, Bhandari M, Stephen D, et al. Development of the radiographic union score for tibial fractures for the assessment of tibial fracture healing after intramedullary fixation. J Trauma. 2010;68(3):629–632. doi:10.1097/TA.0b013e3181a7c16d
23. Megas P. Classification of non-union. injury. 2005;10:8.
24. Portal-Nunez S, Lozano D, Esbrit P. Role of angiogenesis on bone formation. Histol Histopathol. 2012;27(5):559–566. doi:10.14670/HH-27.559
25. Berner A, Reichert JC, Muller MB, et al. Treatment of long bone defects and non-unions: from research to clinical practice. Cell Tissue Res. 2012;347(3):501–519. doi:10.1007/s00441-011-1184-8
26. Dickson K, Katzman S, Delgado E, Contreras D. Delayed unions and nonunions of open tibial fractures. Correlation with arteriography results. Clin Orthop Relat Res. 1994;302:189–193.
27. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430–1437. doi:10.2106/JBJS.D.02215
28. Scaglione M, Fabbri L, Dell’Omo D, Gambini F, Guido G. Long bone nonunions treated with autologous concentrated bone marrow-derived cells combined with dried bone allograft. Musculoskelet Surg. 2014;98(2):101–106. doi:10.1007/s12306-013-0271-2
29. Garg NK, Gaur S, Sharma S. Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand. 1993;64(6):671–672.
30. Leonardi E, Devescovi V, Perut F, Ciapetti G, Giunti A. Isolation, characterisation and osteogenic potential of human bone marrow stromal cells derived from the medullary cavity of the femur. Chir Organi Mov. 2008;92(2):97–103. doi:10.1007/s12306-008-0057-0
31. Paley D, Young MC, Wiley AM, Fornasier VL, Jackson RW. Percutaneous bone marrow grafting of fractures and bony defects. An experimental study in rabbits. Clin Orthop Relat Res. 1986;208:300–312.
32. Phedy P, Dilogo IH, Jusuf AA, Kholinne E, Efendi Z. Iliac crest and femoral bone marrow as the source of plastic-adherent cells. Med J Indonesia. 2011. doi:10.13181/mji.v20i2.436
33. Tiedeman JJ, Connolly JF, Strates BS, Lippiello L. Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix. An experimental study in dogs. Clin Orthop Relat Res. 1991;268:294–302.
34. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am. 1997;79(11):1699–1709. doi:10.2106/00004623-199711000-00012
35. Centeno CJ, Schultz JR, Cheever M, Freeman M, Robinson B, Faulkner SJ. A case series of percutaneous treatment of non-union fractures with autologous, culture expanded, bone marrow derived, mesenchymal stem cells and platelet lysate. J Bioeng Biomed Sci. 2011;01(S2). doi:10.4172/2155-9538.S2-007
36. Hernigou P. Growth factors released from bone marrow are promising tools in orthopedic surgery. Rev Rhum Engl Ed. 1998;65(2):79–84.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]